QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.116517v1 321/2/673    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, X.-Y. Articles by Evers, R. Search for Related Content PubMed PubMed Citation Articles by Chu, X.-Y. Articles by Evers, R.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Department of Drug Metabolism, Merck & Co., Rahway, New Jersey

Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor recently approved for the treatment of type 2 diabetes, is excreted into the urine via active tubular secretion and glomerular filtration in humans. In this report, we demonstrate that sitagliptin is transported by human organic anion transporter hOAT3 (K_m = 162 µM), organic anion transporting polypeptide OATP4C1, and multidrug resistance (MDR) P-glycoprotein (Pgp), but not by human organic cation transporter 2 hOCT2, hOAT1, oligopeptide transporter hPEPT1, OATP2B1, and the multidrug resistance proteins MRP2 and MRP4. Our studies suggested that hOAT3, OATP4C1, and MDR1 Pgp might play a role in transporting sitagliptin into and out of renal proximal tubule cells, respectively. Sitagliptin did not inhibit hOAT1-mediated cidofovir uptake, but it showed weak inhibition of hOAT3-mediated cimetidine uptake (IC₅₀ = 160 µM). hOAT3-mediated sitagliptin uptake was inhibited by probenecid, ibuprofen, furosemide, fenofibric acid, quinapril, indapamide, and cimetidine with IC₅₀ values of 5.6, 3.7, 1.7, 2.2, 6.2, 11, and 79 µM, respectively. Sitagliptin did not inhibit Pgp-mediated transport of digoxin, verapamil, ritonavir, quinidine, and vinblastine. Cyclosporine A significantly inhibited Pgp-mediated transport of sitagliptin (IC₅₀ = 1 µM). Our data indicate that sitagliptin is unlikely to be a perpetrator of drug-drug interactions with Pgp, hOAT1, or hOAT3 substrates at clinically relevant concentrations. Renal secretion of sitagliptin could be inhibited if coadministered with OAT3 inhibitors such as probenecid. However, the magnitude of interactions should be low, and the effects may not be clinically meaningful, due to the high safety margin of sitagliptin.

Address correspondence to: Dr. Xiaoyan Chu, Merck & Co., RY80-141, 126 East Lincoln Ave., Rahway, NJ 07065. E-mail: xiaoyan_chu{at}merck.com

This article has been cited by other articles:

				M. V. S. Varma, A. H. Eriksson, G. Sawada, Y. A. Pak, E. J. Perkins, and C. L. Zimmerman Transepithelial Transport of the Group II Metabotropic Glutamate 2/3 Receptor Agonist (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and Its Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344) Drug Metab. Dispos., January 1, 2009; 37(1): 211 - 220. [Abstract] [Full Text] [PDF]

				I. Knutter, C. Wollesky, G. Kottra, M. G. Hahn, W. Fischer, K. Zebisch, R. H. H. Neubert, H. Daniel, and M. Brandsch Transport of Angiotensin-Converting Enzyme Inhibitors by H+/Peptide Transporters Revisited J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 432 - 441. [Abstract] [Full Text] [PDF]

				D. Q. Pham, A. Nogid, and R. Plakogiannis Sitagliptin: A novel agent for the management of type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531. [Abstract] [Full Text] [PDF]